eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
4/2020
vol. 36
 
Share:
Send email
Share:
Case report

COVID-19 in two patients with multiple sclerosis treated with beta interferons

Karolina Kania
1
,
Elżbieta Tokarz-Kupczyk
1
,
Alicja Kalinowska-Łyszczarz
2

  1. Poznan University of Medical Sciences, Department of Neurology
  2. Poznan University of Medical Sciences, Department of Neurology, Division of Neurochemistry and Neuropathology
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (4), 327–334
Online publish date: 2021/12/06
Article file
- 05R_IPiN_FARM_2020-4C_AKC.pdf  [0.13 MB]
Get citation
 
 
1. Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G. SARS CoV-2 and Mu`ltiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. Ann Neurol. 2020 Jun;87(6):794-797.
2. Bartosik-Psujek H, Adamczyk-Sowa M, Kalinowska A, Kułakowska A. Stanowisko dot. leczenia SM w przypadku ryzyka zakażenia koronawirusem wywołującym COVID-19. Pol. Przegl. Neurol 2020;16(1):59-61.
3. Bollo L, Guerra T, Bavaro DF, Monno L, Saracino A, Angarano G, Paolicelli D et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fin golimod and teriflunomide. J Neurol Sci. 2020 Jul 4;416:117011.
4. Carandini T, Pietroboni AM, Sacchi L, De Riz MA, Pozzato M, Arighi A et al. Alemtuzumab in multiple sclerosis dur ing the COVID-19 pandemic: A mild uncomplicated infec tion despite intense immunosuppression. Mult Scler. 2020 Sep;26(10):1268-1269.
5. Ciardi MR, Zingaropoli MA, Pasculli P, Perri V, Tartaglia M, Valeri S, Russo G, Conte A, Mastroianni CM. The peripheral blood immune cell profile in a teriflunomide-treated mul tiple sclerosis patient with COVID-19 pneumonia. J Neu roimmunol. 2020 Jul 15;346:577323. doi: 10.1016/j.jneuro im.2020.577323.
6. De Angelis M, Petracca M, Lanzillo R, Brescia Morra V, Moc cia M. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Mult Scler Relat Disord. 2020 Aug 16;45:102452.
7. Dersch R, Wehrum T, Fähndrich S, Engelhardt M, Rauer S, Berger B. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783.
8. Fernández-Díaz E, Gracia-Gil J, García-García JG, Palao M, Romero-Sánchez CM, Segura T. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab [pub lished online ahead of print, 2020 Jul 17]. Mult Scler Relat Disord. 2020;45:102402. doi:10.1016/j.msard.2020.102402.
9. García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, Talavera B et al. Neurological Comorbidi ty Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients. Front Neurol. 2020 Jul 7;11:781.
10. Gemcioglu E, Davutoglu M, Ozdemir EE, Erden A. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Mult Scler Relat Disord. 2020 Jul; 42:102196. doi: 10.1016/j.msard.2020.102196.
11. Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V et al. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Dis ord. 2020 Aug;43:102222.
12. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS dis ease-modifying therapies. Mult Scler Relat Disord. 2020 Apr;39:102073.
13. Gomez‐Mayordomo, V, Montero‐Escribano, P, Matías‐Guiu, JA, González‐García, N, Porta‐Etessam, J, Matías‐Guiu, J.Clin ical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal. J Med Virol. 2020;1-4.
14. Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab – a pharmacov igilance case series. Mult. Scler. Relat. Disord. 2020.
15. Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG,Zivadinov R. Infections vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines 2020 8(1): 50.
16. Kloc M, Ghobrial RM. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients. Mult Scler Relat Disord. 2020 Jul 31;45:102437.
17. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J et al. Clini cal and immunological assessment of asymptomatic SARS CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-1204.
18. Loonstra FC, Hoitsma E, van Kempen ZLE, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch expe rience. Mult Scler. 2020;26(10):1256-1260.
19. Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Scle rosis. JAMA Neurol. 2020 Jun 26;77(9):1–10.
20. Mantero V, Abate L, Basilico P, Balgera R, Salmaggi A, Nour bakhsh B et al. COVID-19 in dimethyl fumarate-treated pa tients with multiple sclerosis. J Neurol. 2020 Jun 25:1–3. (a)
21. Mantero V, Baroncini D, Balgera R, Guaschino C, Basilico P, Annovazzi P et al. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Aug 31:1–2. (b)
22. Meca-Lallana V, Aguirre C, Beatrizdel Río, Cardeñoso L, Alar con T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020 Jun 15;44:102306.
23. Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020 Jul;42:102120.
24. Rimmer K, Farber R, Thakur K, Braverman G, Podolsky D, Sutherland L et al. Fatal COVID-19 in an MS patient on na talizumab: A case report. Mult Scler J Exp Transl Clin. 2020 Aug 10;6(3):2055217320942931.
25. Severa M, Farina C, Salvetti M, Coccia EM. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection? Front Immunol. 2020 Jun 18;11:1459.
26. Simpson-Yap S. First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are asso ciated with worse COVID-19 outcomes. MSVirtual 2020. Abstract SS02.04.
27. Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020; doi: 10.1016/S1474-4422(20)30147-2.
28. Thakolwiboon S, Zhao-Fleming H, Pan J, Scott JK, Shoji E, Sohn G et al. Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations. Int J MS Care. 2020 Jul Aug;22(4):151-157.
29. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective study. Lancet. (2020) 395:1054–62.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.